SI2053915T1 - Peptidi za blažilno sproščanje mediatorjev vnetja - Google Patents

Peptidi za blažilno sproščanje mediatorjev vnetja

Info

Publication number
SI2053915T1
SI2053915T1 SI200731481T SI200731481T SI2053915T1 SI 2053915 T1 SI2053915 T1 SI 2053915T1 SI 200731481 T SI200731481 T SI 200731481T SI 200731481 T SI200731481 T SI 200731481T SI 2053915 T1 SI2053915 T1 SI 2053915T1
Authority
SI
Slovenia
Prior art keywords
peptides
inflammatory mediators
attenuating
release
attenuating release
Prior art date
Application number
SI200731481T
Other languages
English (en)
Inventor
Indu Parikh
Original Assignee
Biomarck Pharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals, Ltd. filed Critical Biomarck Pharmaceuticals, Ltd.
Publication of SI2053915T1 publication Critical patent/SI2053915T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SI200731481T 2006-07-26 2007-07-26 Peptidi za blažilno sproščanje mediatorjev vnetja SI2053915T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83323906P 2006-07-26 2006-07-26
PCT/US2007/074514 WO2008014414A2 (en) 2006-07-26 2007-07-26 Methods for attenuating release of inflammatory mediators and peptides useful therein
EP07840538.8A EP2053915B1 (en) 2006-07-26 2007-07-26 Peptides for attenuating release of inflammatory mediators

Publications (1)

Publication Number Publication Date
SI2053915T1 true SI2053915T1 (sl) 2014-10-30

Family

ID=38982357

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731481T SI2053915T1 (sl) 2006-07-26 2007-07-26 Peptidi za blažilno sproščanje mediatorjev vnetja

Country Status (22)

Country Link
US (6) US8999915B2 (sl)
EP (2) EP2053915B1 (sl)
JP (2) JP5378998B2 (sl)
KR (1) KR101599894B1 (sl)
CN (2) CN103990111B (sl)
AU (1) AU2007279193B2 (sl)
BR (1) BRPI0714953A2 (sl)
CA (2) CA2658949C (sl)
DK (2) DK2722052T3 (sl)
ES (2) ES2725599T3 (sl)
HK (2) HK1125793A1 (sl)
HR (1) HRP20140587T1 (sl)
IL (1) IL196667A (sl)
MX (1) MX2009000975A (sl)
NO (1) NO20090304L (sl)
PL (2) PL2053915T3 (sl)
PT (1) PT2053915E (sl)
RU (1) RU2423376C2 (sl)
SG (2) SG173411A1 (sl)
SI (1) SI2053915T1 (sl)
WO (1) WO2008014414A2 (sl)
ZA (1) ZA200900550B (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0606445A2 (pt) 2005-01-20 2009-03-10 Biomarck Pharmaceuticals Ltd inibidores de hipersecreÇço de mucina e mÉtodos de uso
JP5378998B2 (ja) 2006-07-26 2013-12-25 バイオマーク・フアーマシユーテイカルズ・リミテツド 炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド
EP2445517B1 (en) * 2009-06-25 2014-07-30 Nestec S.A. Methods for diagnosing irritable bowel syndrome
WO2011060349A1 (en) * 2009-11-13 2011-05-19 North Carolina State University Methods of modulating mesenchymal stem cells
DK2981279T3 (en) 2013-04-05 2019-03-25 Biomarck Pharmaceuticals Ltd MARCKS INHIBITOR PERIODS FOR INHIBITING METASTASES
US10189881B2 (en) 2013-07-26 2019-01-29 The Regents Of The University Of California MPS peptides and use thereof
WO2015095789A2 (en) * 2013-12-20 2015-06-25 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
KR102181548B1 (ko) * 2019-02-20 2020-11-20 한국외국어대학교 연구산학협력단 염증성 질환 또는 자가면역성 질환의 예방 또는 치료 활성을 갖는 펩타이드 및 이의 용도
WO2023212443A1 (en) * 2022-04-25 2023-11-02 Biomarck Pharmaceuticals, Ltd. Peptides and methods of use thereof in treating skin diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61265341A (ja) * 1985-05-17 1986-11-25 Kawasaki Heavy Ind Ltd Ｖ型エンジンのシリンダ−ブロツク構造
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
AU642133B2 (en) 1988-11-18 1993-10-14 Board Of Regents Of The University Of Washington, The HDL-binding proteins
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
WO1993000353A1 (en) 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5298506A (en) 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) 1992-11-09 1999-01-19 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
EP0759768A4 (en) 1994-04-07 2000-08-09 Proteinix Company VASOACTIVE COLON PEPTIDE
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
ES2230078T3 (es) 1999-02-24 2005-05-01 North Carolina State University Procedimientos y composiciones para alternar la secrecion de mucus.
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US6245320B1 (en) 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001020998A1 (en) 1999-09-24 2001-03-29 Linden Technologies, Inc. Drug discovery using gene expression profiling
ES2200787T3 (es) 1999-12-03 2004-03-16 Pfizer Products Inc. Derivados de acetileno como agentes antiinflamatorios/analgesicos.
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
ATE519493T1 (de) 2001-06-26 2011-08-15 Univ North Carolina State Blockierendes peptid für die sekretion von entzündungszellen
JP2004049133A (ja) 2002-07-22 2004-02-19 Kumamoto Technology & Industry Foundation Ｎ−ミリストイルトランスフェラーゼ活性の測定方法
US7598080B2 (en) 2004-08-20 2009-10-06 Carl Deirmengian Diagnostic assay for source of inflammation
US7408030B2 (en) 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
BRPI0606445A2 (pt) 2005-01-20 2009-03-10 Biomarck Pharmaceuticals Ltd inibidores de hipersecreÇço de mucina e mÉtodos de uso
JP5378998B2 (ja) 2006-07-26 2013-12-25 バイオマーク・フアーマシユーテイカルズ・リミテツド 炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド

Also Published As

Publication number Publication date
PL2053915T3 (pl) 2014-12-31
DK2722052T3 (en) 2019-04-29
US20200138898A1 (en) 2020-05-07
KR101599894B1 (ko) 2016-03-04
IL196667A (en) 2017-04-30
CA2842219A1 (en) 2008-01-31
CA2658949C (en) 2014-04-22
AU2007279193B2 (en) 2011-12-01
US20160030509A1 (en) 2016-02-04
US9827287B2 (en) 2017-11-28
HRP20140587T1 (hr) 2014-11-21
ES2488092T3 (es) 2014-08-26
IL196667A0 (en) 2011-08-01
CA2842219C (en) 2017-07-11
US20210260154A1 (en) 2021-08-26
RU2009106673A (ru) 2010-09-10
CN103990111A (zh) 2014-08-20
SG10201500418QA (en) 2015-03-30
EP2053915A4 (en) 2011-06-08
JP5378998B2 (ja) 2013-12-25
AU2007279193A1 (en) 2008-01-31
CN101516190A (zh) 2009-08-26
BRPI0714953A2 (pt) 2013-07-16
CN103990111B (zh) 2016-08-31
WO2008014414A3 (en) 2008-09-25
JP2013241428A (ja) 2013-12-05
NO20090304L (no) 2009-04-21
EP2053915A2 (en) 2009-05-06
HK1125793A1 (en) 2009-08-21
ZA200900550B (en) 2010-03-31
US20180036367A1 (en) 2018-02-08
CN101516190B (zh) 2014-06-11
CA2658949A1 (en) 2008-01-31
PL2722052T3 (pl) 2019-08-30
EP2722052A1 (en) 2014-04-23
SG173411A1 (en) 2011-08-29
US8999915B2 (en) 2015-04-07
JP2009544737A (ja) 2009-12-17
MX2009000975A (es) 2009-04-07
PT2053915E (pt) 2014-08-25
ES2725599T3 (es) 2019-09-25
HK1201190A1 (en) 2015-08-28
US20090203620A1 (en) 2009-08-13
EP2722052B1 (en) 2019-03-20
KR20090037487A (ko) 2009-04-15
EP2053915B1 (en) 2014-06-11
DK2053915T3 (da) 2014-06-30
US20230293629A1 (en) 2023-09-21
JP5819889B2 (ja) 2015-11-24
WO2008014414A2 (en) 2008-01-31
RU2423376C2 (ru) 2011-07-10

Similar Documents

Publication Publication Date Title
IL251419A0 (en) solid forms of ester of cddo
HK1125793A1 (en) Peptides for attenuating release of inflammatory mediators
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
AP2999A (en) Support of UICC-less calls
ZA200710598B (en) Treatment of inflammatory conditions
IL193846A0 (en) Methods for regulating inflammatory mediators and peptides useful therein
WO2009134389A9 (en) An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
EP2214481A4 (en) PROCESS FOR INCREASING THE PERFORMANCE OF LATE FOLLOW-UP
EP2358768A4 (en) Crosslinked polyvinylpyrrolidone compounds
GB0724498D0 (en) Slow release compositions
TWM300818U (en) Structure for accessory of eyeglasses set
SG137808A1 (en) Improved process for the manufacture of c1 - c4 alkyl (meth) acrylates
SG136870A1 (en) High definition audio architecture
EP2321281A4 (en) INFLAMMATORY CONNECTIONS
GB2441543B (en) An array of components
EP2042498A4 (en) CRYSTAL OF BENZOXADIAZOLE DERIVATIVE
TWM298600U (en) Improved structure of clothespin set
TWM311768U (en) Improved structure of A-ladder
IL198836A0 (en) Processes for preparation of 9-haloacetamidomidominocyclines
GB0612370D0 (en) Uses of (S)-clenbuterol
IL202502A (en) Cxcl11 for the treatment of inflammatory diseases
PL380652A1 (pl) Rozcieracz minicząstek
PL383255A1 (pl) Zestaw do realizacji promocji
GB0624215D0 (en) Control of stage effects
TWM299269U (en) Improved range hood structure